BRPI0611095B8 - compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos - Google Patents
compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostosInfo
- Publication number
- BRPI0611095B8 BRPI0611095B8 BRPI0611095A BRPI0611095A BRPI0611095B8 BR PI0611095 B8 BRPI0611095 B8 BR PI0611095B8 BR PI0611095 A BRPI0611095 A BR PI0611095A BR PI0611095 A BRPI0611095 A BR PI0611095A BR PI0611095 B8 BRPI0611095 B8 BR PI0611095B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pde1
- parkinson
- disease
- producing
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 title 1
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- -1 C3-9-cycloalkyl Chemical group 0.000 abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 abstract 1
- TZYQTWHRLVDYPL-UHFFFAOYSA-N 5h-pyrimidin-4-one Chemical compound O=C1CC=NC=N1 TZYQTWHRLVDYPL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 239000000651 prodrug Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68771505P | 2005-06-06 | 2005-06-06 | |
| US60/687.715 | 2005-06-06 | ||
| US60/687,715 | 2005-06-06 | ||
| PCT/US2006/022066 WO2006133261A2 (en) | 2005-06-06 | 2006-06-06 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0611095A2 BRPI0611095A2 (pt) | 2010-12-07 |
| BRPI0611095B1 BRPI0611095B1 (pt) | 2021-02-02 |
| BRPI0611095B8 true BRPI0611095B8 (pt) | 2021-05-25 |
Family
ID=37499079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0611095A BRPI0611095B8 (pt) | 2005-06-06 | 2006-06-06 | compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8273750B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1888534B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5084725B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20140022114A (cg-RX-API-DMAC7.html) |
| CN (2) | CN101248050B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006255028B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0611095B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2611312C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2645371T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006133261A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
| ES2645371T3 (es) | 2005-06-06 | 2017-12-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| EP1919287A4 (en) * | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| US9255099B2 (en) * | 2006-06-06 | 2016-02-09 | Intra-Cellular Therapies, Inc. | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors |
| US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9006258B2 (en) * | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| AU2012204137B2 (en) * | 2007-12-06 | 2015-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR101227738B1 (ko) * | 2007-12-06 | 2013-01-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 유기 화합물 |
| AU2008331833A1 (en) * | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
| US20120070443A1 (en) * | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2638912T3 (es) * | 2008-12-06 | 2017-10-24 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| JP5784501B2 (ja) * | 2008-12-06 | 2015-09-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| BRPI0922351A2 (pt) | 2008-12-06 | 2018-06-05 | Intracellular Therapies Inc | compostos orgânicos |
| MX2011005935A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
| US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| EP2461673A4 (en) | 2009-08-05 | 2013-08-07 | Intra Cellular Therapies Inc | NEW REGULATOR PROTEINS AND HEMMER |
| EP2485771A4 (en) * | 2009-10-08 | 2014-11-12 | Intra Cellular Therapies Inc | TRACER AND METHODS TAGGED ON PHOSPHODIESTERASE 1 |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TW201206937A (en) * | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9428506B2 (en) * | 2012-04-14 | 2016-08-30 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| CN103012287B (zh) * | 2012-12-24 | 2015-06-17 | 济南圣泉唐和唐生物科技有限公司 | 6-氯-3-甲基脲嘧啶的制备方法 |
| WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
| ES2871327T3 (es) | 2013-03-15 | 2021-10-28 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP |
| RU2679142C2 (ru) * | 2013-03-15 | 2019-02-06 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| CN105658222A (zh) * | 2013-06-21 | 2016-06-08 | 细胞内治疗公司 | 游离碱晶体 |
| EP3091983B1 (en) | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
| WO2015196186A1 (en) | 2014-06-20 | 2015-12-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| WO2016022825A1 (en) * | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016022836A1 (en) * | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016022893A1 (en) * | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3193878B1 (en) * | 2014-09-17 | 2021-01-06 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
| EP3226870B1 (en) | 2014-12-06 | 2019-09-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP6608933B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| JP6996074B2 (ja) * | 2016-06-28 | 2022-01-17 | 住友ゴム工業株式会社 | ゴム組成物およびタイヤ |
| EP3970719A1 (en) | 2016-09-12 | 2022-03-23 | Intra-Cellular Therapies, Inc. | Pde1 inhibitor for use in a method of treatment or prophylaxis of inflammation and/or an inflammatory disease or disorder |
| JP7111720B2 (ja) | 2016-12-28 | 2022-08-02 | ダート・ニューロサイエンス・エルエルシー | Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物 |
| CN109422749B (zh) * | 2017-08-21 | 2023-01-24 | 重庆医药工业研究院有限责任公司 | 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物 |
| US11434247B1 (en) | 2017-11-27 | 2022-09-06 | Dart Neuroscience Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| AU2019275453B2 (en) | 2018-05-25 | 2023-12-21 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3908285A4 (en) * | 2019-01-07 | 2022-10-19 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| US11628171B2 (en) | 2019-03-13 | 2023-04-18 | Children's Medical Center Corporation | Method for treating brain or nerve injury |
| WO2020210614A1 (en) | 2019-04-12 | 2020-10-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7612672B2 (ja) * | 2019-09-03 | 2025-01-14 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規化合物 |
| US20230355625A1 (en) * | 2019-11-27 | 2023-11-09 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| WO2021226407A1 (en) | 2020-05-06 | 2021-11-11 | Intra-Cellular Therapies, Inc. | Free base crystals |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| WO2022026417A1 (en) * | 2020-07-26 | 2022-02-03 | Intra-Cellular Therapies, Inc. | Novel uses |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6032638B2 (ja) | 1976-09-01 | 1985-07-29 | 武田薬品工業株式会社 | ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体 |
| WO1982003626A1 (en) | 1981-04-22 | 1982-10-28 | Gauri Kailash Kumar | New derivatives of pyrazolo(3,4-d)pyrimidine,preparation method thereof and remedy containing them |
| US4469868A (en) | 1982-05-24 | 1984-09-04 | Warner-Lambert Company | Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines |
| US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| KR920004437B1 (ko) | 1989-09-12 | 1992-06-05 | 삼성전자 주식회사 | 금전등록기의 거래선 관리방법 |
| NZ238609A (en) * | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
| US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| HUT72640A (en) * | 1993-02-26 | 1996-05-28 | Schering Corp | 2-benzyl-polycyclic guanine derivatives, pharmaceutical compositions containing them and process for preparing them |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US5824683A (en) * | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0946523A1 (en) | 1996-12-23 | 1999-10-06 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| AU7141198A (en) | 1997-06-13 | 1998-12-30 | Arthrocare Corporation | Electrosurgical systems and methods for recanalization of occluded body lumens |
| US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| AU3053999A (en) | 1998-03-31 | 1999-10-25 | Kyowa Hakko Kogyo Co. Ltd. | Nitrogenous heterocyclic compounds |
| US6133273A (en) | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| AU5889100A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| DE19931206A1 (de) * | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
| ES2250186T3 (es) | 1999-09-10 | 2006-04-16 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
| US6372743B1 (en) | 1999-09-30 | 2002-04-16 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
| SK4562002A3 (en) | 1999-10-11 | 2003-04-01 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| JP2004500425A (ja) | 2000-04-19 | 2004-01-08 | リリー アイコス リミテッド ライアビリティ カンパニー | パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用 |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| BR0208078A (pt) | 2001-03-16 | 2004-03-02 | Pfizer | Compostos pirazol[4,3-d]pirimidinona como inibidores de cgmp pde |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| MXPA04001891A (es) | 2001-08-28 | 2004-06-15 | Schering Corp | Inhibidores policiclicos de guanina fosfodiesterasa v. |
| US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
| CN1585771A (zh) | 2001-11-09 | 2005-02-23 | 先灵公司 | 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂 |
| NZ535354A (en) | 2002-02-15 | 2008-01-31 | Merckle Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| IL163575A0 (en) | 2002-02-21 | 2005-12-18 | Univ Rockefeller | Compositions and method for regulation of calcium-dependent signalling in brain |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| WO2004087906A1 (en) | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| KR20050115331A (ko) | 2003-04-01 | 2005-12-07 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 불임증 포스포디에스터라제의 억제제 |
| AU2004270713A1 (en) | 2003-09-05 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
| ES2645371T3 (es) * | 2005-06-06 | 2017-12-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| US9255099B2 (en) | 2006-06-06 | 2016-02-09 | Intra-Cellular Therapies, Inc. | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors |
| US20070286890A1 (en) | 2006-06-07 | 2007-12-13 | John Garnett Walt | Eyelash applicator and method |
| US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| KR101227738B1 (ko) | 2007-12-06 | 2013-01-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 유기 화합물 |
| AU2008331833A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
| WO2009107578A1 (ja) | 2008-02-25 | 2009-09-03 | Sato Kenji | 音響装置 |
| ES2638912T3 (es) | 2008-12-06 | 2017-10-24 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
| MX2011005935A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| BRPI0922351A2 (pt) | 2008-12-06 | 2018-06-05 | Intracellular Therapies Inc | compostos orgânicos |
| JP5784501B2 (ja) | 2008-12-06 | 2015-09-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| EP2485771A4 (en) | 2009-10-08 | 2014-11-12 | Intra Cellular Therapies Inc | TRACER AND METHODS TAGGED ON PHOSPHODIESTERASE 1 |
| JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| RU2679142C2 (ru) | 2013-03-15 | 2019-02-06 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
-
2006
- 2006-06-06 ES ES06772397.3T patent/ES2645371T3/es active Active
- 2006-06-06 BR BRPI0611095A patent/BRPI0611095B8/pt active IP Right Grant
- 2006-06-06 AU AU2006255028A patent/AU2006255028B2/en active Active
- 2006-06-06 EP EP06772397.3A patent/EP1888534B1/en active Active
- 2006-06-06 CN CN2006800269736A patent/CN101248050B/zh active Active
- 2006-06-06 CN CN2013102507232A patent/CN103467471A/zh active Pending
- 2006-06-06 WO PCT/US2006/022066 patent/WO2006133261A2/en not_active Ceased
- 2006-06-06 KR KR1020147002847A patent/KR20140022114A/ko not_active Ceased
- 2006-06-06 US US11/916,761 patent/US8273750B2/en active Active
- 2006-06-06 CA CA2611312A patent/CA2611312C/en active Active
- 2006-06-06 JP JP2008515858A patent/JP5084725B2/ja active Active
-
2008
- 2008-01-03 KR KR1020087000132A patent/KR101478368B1/ko active Active
-
2012
- 2012-05-22 JP JP2012116786A patent/JP5649614B2/ja active Active
- 2012-07-18 US US13/552,381 patent/US9000001B2/en active Active
-
2014
- 2014-09-10 JP JP2014184489A patent/JP2015007121A/ja active Pending
-
2015
- 2015-03-27 US US14/671,531 patent/US9624230B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008545783A (ja) | 2008-12-18 |
| EP1888534B1 (en) | 2017-07-26 |
| CA2611312C (en) | 2013-12-03 |
| JP2015007121A (ja) | 2015-01-15 |
| EP1888534A4 (en) | 2010-06-16 |
| AU2006255028B2 (en) | 2012-04-19 |
| US9000001B2 (en) | 2015-04-07 |
| JP2012180369A (ja) | 2012-09-20 |
| KR20140022114A (ko) | 2014-02-21 |
| US20150197528A1 (en) | 2015-07-16 |
| BRPI0611095A2 (pt) | 2010-12-07 |
| JP5649614B2 (ja) | 2015-01-07 |
| US9624230B2 (en) | 2017-04-18 |
| CN101248050B (zh) | 2013-07-17 |
| WO2006133261A3 (en) | 2007-06-21 |
| JP5084725B2 (ja) | 2012-11-28 |
| US20080188492A1 (en) | 2008-08-07 |
| CN103467471A (zh) | 2013-12-25 |
| CN101248050A (zh) | 2008-08-20 |
| ES2645371T3 (es) | 2017-12-05 |
| KR101478368B1 (ko) | 2014-12-31 |
| CA2611312A1 (en) | 2006-12-14 |
| AU2006255028A1 (en) | 2006-12-14 |
| BRPI0611095B1 (pt) | 2021-02-02 |
| KR20080028903A (ko) | 2008-04-02 |
| US20130018063A1 (en) | 2013-01-17 |
| WO2006133261A2 (en) | 2006-12-14 |
| EP1888534A2 (en) | 2008-02-20 |
| US8273750B2 (en) | 2012-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0611095B8 (pt) | compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos | |
| PH12012501122A1 (en) | Pteridinones as inhibitors of polo-like kinase | |
| MX2010007746A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de diana de rapamicina de mamifero quinasa y fosfatidilinositol quinasa y su sintesis. | |
| WO2009098715A3 (en) | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents | |
| TNSN08478A1 (en) | Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders | |
| WO2008058126A3 (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| PE20191105A1 (es) | Inhibidores de moleculas pequenas de lafamilia de quinasas jak | |
| EA201170771A1 (ru) | Органические соединения | |
| ECSP055899A (es) | Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos | |
| UY31193A1 (es) | Derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]-piridazina, su preparasción y su aplicación en terapéutica | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| WO2007040438A3 (en) | Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders | |
| NI201000143A (es) | Derivados bicíclicos heterocíclicos o espirobicíclicos heterocíclicos enlazados, de pirazolo[1,5-a] pirimidinas, procedimientos para su preparación y usos de los mismos. | |
| ATE437872T1 (de) | Proteinkinaseinhibitoren | |
| EA201001518A1 (ru) | Производные 1-гетероциклил-1,5-дигидропиразоло[3,4-d]пиримидин-4-она и их применение в качестве модуляторов pde9a | |
| WO2008002244A8 (en) | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3) | |
| CL2008001345A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras. | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| BR112012010041A2 (pt) | derivados de imidazo [1,2-b] piridazina e seu uso como inibidores de pde10 | |
| WO2012048129A3 (en) | Inhibitors of polo-like kinase | |
| WO2008070313A3 (en) | 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use | |
| WO2009013348A3 (en) | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions | |
| MX336332B (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: CONFORME PARECER/INPI/PROC/DIRAD NO18/08 APRESENTE DOCUMENTO DE PROCURACAO DEVIDAMENTE AUTENTICADO OUTORGADO EM DATA ANTERIOR OU COINCIDENTE A DO PRIMEIRO ATO DA PARTE NO PROCESSO, COMPROVANDO PODERES PARA REPRESENTAR O DEPOSITANTE PERANTE O INPI A EPOCA DO DEPOSITO. |
|
| B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |